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Abstract
Background: To evaluate the efficacy and outcomes of hypofractionated stereotactic radiotherapy (HSRT) for brain
metastases > 3 cm.
Methods: From March 2003 to October 2009, 40 patients with brain metastases larger than 3 cm were treated by
HSRT. HSRT was applied in 29 patients for primary treatment and in 11 patients for rescue. Single brain metastasis
was detected in 21 patients. Whole brain radiotherapy was incorporated into HSRT in 10 patients for primary
treatment. HSRT boosts were applied in 23 patients. The diameters of the brain metastases ranged from 3.1 to 5.5
cm (median, 4.1 cm). The median prescribed dose (not including HSRT boosts) was 40 Gy (range, 20-53 Gy) with a
median of 10 fractions (range, 4-15 fractions) to the 90% isodose line. The median dose of the boost was 20 Gy
(range, 10-35 Gy) in 4 fractions (range, 2-10 fractions).
Result: The median overall survival time was 15 months. The overall survival and local control rate at 12 months
was 55.3% and 94.2%, respectively. Four patients experienced local progression of large brain metastases. Nine
patients died of intracranial disease progression. One patient died of radiation necrosis with brain edema.
Conclusion: HSRT was a safe and effective treatment for patients with brain metastases ranged from 3.1 to 5.5 cm.
Dose escalation of HSRT boost may improve local control with an acceptable toxicity.
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Background
Twenty to 40% of patients with cancer will develop
brain metastases that will result in an impaired quality
of life and a reduced survival time [1]. The treatment
regimens for brain metastasis include corticosteroids,
surgery, whole brain radiotherapy (WBRT), and stereo-
tactic radiosurgery (SRS). The survival of patients with a
single metastasis can be prolonged by the combination
of surgery and WBRT [2]. For surgically unresectable
brain metastases, the combination of SRS and WBRT
can prolong the survival of patients with solitary metas-
tases and improve local control in patients with 2 or 3
brain metastases [3]. The prognoses of patients under-
going SRS have been shown to be related to the
prescribed dose of the treatment as well as the tumor
volume. Low doses and large tumor volumes are adverse
factors for local control [4]. Due to the limits of normal
tissue tolerance, the Radiation Therapy Oncology Group
(RTOG) 90-05 recommended radiation doses of 24 Gy,
18 Gy, and 15 Gy for recurrent brain tumors with maxi-
mum diameters of 20 mm or less, 21-31 mm, and 31-40
mm, respectively [5]. Reports have shown that poor
prognoses were associated with brain metastases greater
than 3 cm in diameter [6]. In recent years, hypofractio-
nated stereotactic radiotherapy (HSRT) has been
reported to result in outcomes that are similar to SRS
treatment [7-11]. HSRT has a radiobiological advantage
over SRS and provides better protection of normal tis-
s u e s ;t h e r e f o r e ,H S R Tm a yb eam o r es u i t a b l et h e r a p y
for large-volume brain metastases. This paper reports
preliminary results of a retrospective study of the use of
HSRT to treat brain metastases in patients with tumors
larger than 3 cm in diameter that was conducted at the
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Methods
Patient data
From May 2003 to October 2009, 40 patients with brain
metastases greater than 3 cm in diameter were treated
with HSRT. The enrollment criteria included the follow-
ing: 1, maximum diameter of brain metastasis greater
than 30 mm; 2, survival expectancy greater than 3
months; and 3, RPA grade of 1-2 (patients with RPA
grade 3 induced by brain metastasis were also enrolled).
Of these 40 patients, 29 were treated for primary brain
metastases, and 11 were treated for recurrent disease
after WBRT. Among the patients undergoing primary
treatment, 19 were treated with HSRT alone, and 10
were treated with WBRT plus HSRT. Twenty-one
patients had a solitary brain lesion, while 19 patients had
2 to 4 lesions. The pathologies of the primary lesions
included 20 patients with non-small-cell lung cancer, 10
patients with small-cell lung cancer, 3 patients with
breast cancer, and 7 patients with other cancers. Detailed
patient characteristics are summarized in Table 1.
Treatment
HSRT was performed in all patients on an outpatient
basis. Patients were immobilized in the supine position
in a tight thermoplastic stereotactic head mask.
Enhanced helical computed tomography (CT) images of
3-mm thickness were obtained using the Novalis™
Brain Scan Treatment Planning System. Gross tumor
volume (GTV) was defined by the contrast-enhanced
tumor on CT scans with reference to magnetic reso-
nance imaging (MRI) images. Planning target volume
(PTV) was defined by adding a margin of 2 mm to the
GTV. HSRT was performed using a dynamic conformal
arc treatment with a Varian linear accelerator.
The PTV was enclosed by a 90% isodose curve of the
prescribed dose in HSRT. The median dose of the first
course of HSRT was 40 Gy (range of 20-53 Gy) with a
median of 10 fractions(f) (range of 4-15 f). Twenty-three
patients were given an HSRT boost 1-3 months after the
f i r s tc o u r s eo fH S R T .T h em e d i a nd o s eo ft h eb o o s tw a s
20 Gy (range, 10-35 Gy) in 4 f (range, 2-10 f). The univer-
sal dose fractionation of 40 Gy/20 f or 30 Gy/10 f was
used for WBRT. In patients with multiple brain metas-
tases, other metastases were also treated with HSRT
simultaneously or sequentially according to position.
Detailed HSRT characteristics are summarized in Table 2.
Follow-up and statistics
Patients underwent clinical follow-up examinations
every 3 months so that we could evaluate their disease
status, neurologic symptoms, and performance status.
Every patient had at least 1 MRI exam. Each lesion was
measured for local tumor response, and tumors were
graded according to the following 4 categories: 1) com-
plete remission (CR), indicating the disappearance of all
enhanced lesions on MRI; 2) partial remission (PR),
indicating evidence of a more than 50% reduction in the
cross-sectional dimensions of the tumor on MRI images;
3) progressive disease (PD), indicating a more than 25%
increase in size; or 4) stable disease (SD), indicating all
other responses. Local tumor control was defined as CR,
PR, or SD. Failure to control the local tumor was
defined as PD. The appearance of new lesions was
defined as intracranial distant metastasis. Survival time
was calculated as the time from the beginning of HSRT
to follow-up or death. Toxicity was recorded according
to the National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE, version 3.0).
We evaluated local tumor control, intracranial distant
metastasis, overall survival, and toxicity as endpoints.
Calculations were performed using SPSS 13.0 software
in Windows XP (IBM Corporation, Chicago, IL, USA).
Survival rate was calculated using the Kaplan-Meier
method. Univariate log-rank tests were used to assess
the significance of the association between prognostic
factors, survival, and local tumor control.
Results
Survival and local control
At the time of the last follow-up that was conducted in
October of 2010, 8 patients had survived, and 32 were
deceased. The median follow-up time of alive patients
was 16 months (11-38 months). The median survival
time was 15 months [5.5-38 months, 95% Confidence
Interval (CI): 10.5-19.5 months]. The mean survival
time was 17.8 months (5.5-38 months, 95% CI: 14.6-
21.1 months). The overall survival rate at 1, 2, and 3
years was 55.3%, 23.8%, and 15.9%, respectively. Four
patients experienced local progression of large lesions.
Among these, 2 had been treated for primary brain
metastases (1 with HSRT alone and 1 with HSRT plus
WBRT), and 2 had undergone salvage treatment. The
local control rate at 1, 2, and 3 years was 94.2%,
94.2%, and 78.5%, respectively. Out of the 17 patients
who developed new brain metastases, 15 had been
treated for primary brain metastases (10 with HSRT
alone and 5 with HSRT plus WBRT), and 2 had
undergone salvage treatment. Two patients developed
local progressions and new brain metastases simulta-
neously. In patients with multiple metastases, no pro-
gression was observed in smaller lesions treated with
HSRT simultaneously or sequentially. The intracranial
disease-free rate at 1, 2, and 3 years was 64.6%, 41.0%,
and 41.0%, respectively.
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Of the 32 patients who died, 12 died of extracranial dis-
ease progression, 9 died of intracranial disease progres-
sion, 4 died of pulmonary infection, 2 died of depletion,
1 each died of brain edema, secondary malignancy, or
complications after craniotomy. The cause of death for
the remaining 2 patients was unknown.
Prognostic factors
The following factors were analyzed in order to deter-
mine whether they were related to the prognosis of sur-
vival and local tumor control: gender, age, treatment
character (primary, salvage), number of brain metastases
(1, > 1), status of primary tumor, status of extracranial
metastases, Karnofsky performance score (KPS), and
Table 1 Patient Characteristics
Primary treatment with HSRT
alone
Primary treatment with WBRT +
HSRT
Salvage treatment with
HSRT
Total number 19 10 11
Gender
Male 13 6 5
Female 6 4 6
Median Age, y (range) 55 (38-87) 56 (40-76) 47 (35-73)
≥ 65 6 4 1
<6 5 1 3 6 1 0
No. of brain metastases
11 0 4 5
29 3 2
30 2 4
40 1 0
Primary tumor
Non-small-cell lung cancer 10 6 4
Small-cell lung cancer 2 2 6
Breast cancer 1 2 0
Other 6 0 1
Control of primary tumor
Controlled 16 6 9
Uncontrolled 3 4 2
Extracranial metastasis
No 7 2 8
Yes 12 8 3
Karnofsky Performance Score
≥ 80 10 3 7
<8 0 9 7 4
RPA class
14 1 7
21 2 8 4
33 1 0
Hypofractionated stereotactic radiotherapy
(HSRT) Boost
13 1 9
Table 2 HSRT Characteristics
Median
(range)
Maximum diameter of brain metastasis (cm) 4.1 (3.1-5.5)
Gross Tumor Volume (GTV) of the first course of HSRT
(cm
3)
17.48 (6.28-
64.65)
Dose of the first course of HSRT (Gy) 40 (20-53)
Fractions of the first course of HSRT 10 (4-15)
No. of patients receiving HSRT boost 23
Dose of HSRT boost (Gy) 20 (10-35)
Fractions of HSRT boost 4 (2-10)
GTV of HSRT boost (cm
3) 10.22 (2.03-
37.51)
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of 80 or more were advantageous prognostic factors of
survival (Table 3). No factor was identified as a signifi-
cant predictor of local tumor control (Table 4).
Toxicity
No acute toxicity was observed. Late toxicity consisting
of grade 3-5 brain edema occurred in 5 patients, and it
presented as uncontrollable headaches. Four out of 5 of
these patients developed new brain metastases and
underwent salvage treatment consisting of SRS/HSRT or
WBRT. Only 1 patient died of brain edema.
Discussion
It has been reported that surgery plus WBRT is superior
to WBRT alone for patients with solitary brain metas-
tases and good performance statuses [12-14]. However,
most patients with brain metastases are not suitable for
craniotomies due to the patients’ physical statuses, the
positions of the metastatic tumor, and the distribution
of medical resources. As an alternative to surgery, SRS
has been successfully used to treat brain metastasis and
generally results in satisfactory local control. Metastatic
brain tumors are normally round or oval with little infil-
tration, making it one of the most suitable targets for
SRS. Some studies, including one randomized trial, have
shown that, compared to treatment with WBRT alone,
SRS plus WBRT resulted in greater improvement in
local control of brain metastases and survival times in
patients with favorable prognostic factors [2,3].
With SRS treatment, there is a steep dose fall-off in
the target region. However, with an increase of target
size, the dose gradient decreases. Therefore, while still
limited by normal tissue tolerance, the dose of SRS
treatment has to decrease with the increase of target
size. As a result, the prescribed doses suggested by
RTOG 90-05 are 24 Gy, 18 Gy, and 15 Gy for recurrent
brain tumors with maximum diameters ≤ 20 mm, 21-31
mm, and 31-40 mm, respectively. It is known that a lar-
ger dose is needed to obtain the same tumor control
probability for larger tumors. Because of this, large
tumor volumes are associated with poor local control in
brain metastases [4,6,15].
In recent years, reports have demonstrated that brain
metastases treated by HSRT resulted in similar survival
durations and long-term toxicities when compared with
those treated with only SRS treatments. HSRT is per-
formed with a noninvasive mask and with radiation
given in several fractions, which is more comfortable for
the patient and has greater advantages with respect to
radiobiology and normal tissue protection [16,17]. There
is no unified dose fractionation for HSRT. Fahrig et al.
compared the fractionations of 5 × 6-7 Gy, 10 × 4 Gy,
and 7 × 5 Gy for the treatment of brain metastases and
concluded that in cases with brain metastases where the
tumor volume is greater than 15 cm
3 (diameter > 3 cm)
and with regards to toxicity, 10 × 4 Gy was more advan-
tageous than a regimen with less fractionation. However,
univariate analysis showed that large tumor volumes are
still a disadvantageous prognostic factor [18]. In our
study, most of our patients were treated with a fractio-
n a t i o nr e g i m e no f1 0×3 - 5G y ,a n d2 3o u to f4 0
patients received an HSRT boost 1-3 months after the
first course of HSRT. Only 10% of patients (4 out of 40)
were found to have local recurrence. In fact, the local
control rate (94.2% at 1 year) was comparable to other
studies of SRS and HSRT treatments. Therefore, we
concluded that brain metastasis with tumors > 3 cm can
be well controlled with higher doses of radiation.
Patients in our study had a median survival time of 15
months, which was greater than that of most other
reports of SRS/HSRT treatments [8-11,17,19]. Though
this may be a result of patient selection, our study also
revealed that local control may translate to survival
advantages in patients with metastatic brain tumors > 3
cm.
The univariate analysis showed that a controlled pri-
mary tumor and a good performance score were asso-
ciated with better survival. However, contrary to
previous studies, our data showed that RPA class was
not a significant factor predicting survival time [20,21].
RPA class was not found to be relevant with survival
Table 3 Log-rank Tests for Prognostic Factors Affecting
Overall Survival
Factors P-value
Gender 0.077
Age (≥ 65 y vs. < 65 y) 0.238
Treatment character (primary vs. recurrent) 0.725
No. of brain metastases (solitary vs. multiple) 0.189
Primary tumor (controlled vs. uncontrolled) < 0.001
Extracranial metastasis (yes vs. no) 0.453
KPS (≥ 80 vs. < 80) 0.004
RPA class 0.093
Table 4 Log-rank Tests for Prognostic Factors Affecting
Local Tumor control
Factors P-value
Gender 0.698
Age (≥ 65 y vs. < 65 y) 0.971
Treatment character (primary vs. recurrent) 0.914
No. of brain metastases (solitary vs. multiple) 0.997
Primary tumor (controlled vs. uncontrolled) 0.394
Extracranial metastasis (yes vs. no) 0.667
KPS (≥ 80 vs. < 80) 0.085
RPA class 0.811
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prognostic factors, including tumor volume, were found
to be relevant with respect to local tumor control. This
suggests that dose escalation could be used to decrease
the harmful effects of large tumor volume on local
control.
Five patients developed serious late toxicities that pre-
sented as brain edema. Four of them, however, also had
new brain metastases and underwent salvage treatment.
Only 1 patient definitely died of brain edema and necro-
sis was displayed on MRI exams, and there was no evi-
dence of intracranial recurrence in this patient. This
patient had a brain metastasis in left temporal lobe from
lung adenocarcinoma. She was first arranged WBRT
with a dose fractionation of 40 Gy/15 f. Four months
after WBRT, symptoms recrudesced and recurrence was
detected On MRI. Then HSRT with a dose fractionation
of 27 Gy/9f and boost of 24 Gy/3f was prescribed to the
recurrent lesion. Eight months later, she developed epi-
lepsy and edema with necrosis was displayed on MRI.
The patient refused further treatment including cerebral
ventricular shunt. Finally she died 12 months after the
performance of HSRT with no evidence of tumor pro-
gression. Though in some cases it was difficult to deter-
mine the cause of the brain edema when suspicious
recurrence existed, her death was deemed as treatment
related. Nevertheless, she gained 12 months survival
time from brain metastasis recurrence and we supposed
the edema may be released by cerebral ventricular shunt
if there was no tumor progression. So the toxicity was
deemed as acceptable concerning good local control.
The diameters of the brain metastases in this study
ranged from 3.1 to 5.5 cm (median, 4.1 cm). It was
unknown whether HSRT was suitable for bigger lesions
beyond this range. Since large brain metastases have
mass effect and normally induce obvious brain edema,
we recommend HSRT should be arranged with cautions
in case of brain metastases > 5.5 cm.
Conclusion
In conclusion, we found that HSRT was a safe and
effective therapeutic option for patients with brain
metastases ranged form 3.1 to 5.5 cm. Dose escalation
of the HSRT boost after the first course of HSRT when
many tumors were reduced in volume may improve
local control, while the dose was still within the limits
of acceptable toxicity. Due to the small sample size in
this study, further research is needed.
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